Back to Home
Home >> Biotechnology /Genomics and Intellectual Property >>Biotechnology Entrepreneurship >> New Company Should Have a Focus
Back to Home

New Company Should Have a Focus
Transformation of an important discovery or a .brilliant idea into a commercial opportunity is not always easy, but some young biotechnology companies have done it successfully. We would examine some of the questions, which a company faces while attempting to achieve success in this venture. One of the basic questions, a new company would have to address is to announce or display its focus. For instance, Amgen (California, USA) is a 20 years old pharmaceutical company, which succeeded due to its superb early product selection, so that it succeeded in getting its product to the market. Other successful companies include Sugen (USA), Enzon (USA), Morphosys (Germany) and Vertex (Cambridge, UK). But such a focus can also meet failure, when the selected product fails in clinical trials.' British Biotechnology
(UK) is an example, whose matrix metalloproteinase inhibitor program failed indeed.

Young companies should also be careful in focusing their attention on product development and/or R and D (Research and Development). In the field of drug discovery and development, the company may have skill for drug discovery through R and D, but may not be equipped for drug development. A small young company may enter into drug discovery or clinical trials without a realistic estimate of cost and the risk involved. For instance, even the simplest phase I clinical study may cost $ 250,000, which is much more than a single experiment on the bench. One should also assess the treatment for which the drug is being developed, since a single phase III study of a drug for heart stroke will cost $ 30 million, but that for treatment for migraine will cost only one tenth of this amount. Planning, therefore, is essential to avoid surprises that may prove fatal for the company.